Download PDF
Geriatrie up2date 2019; 1(02): 94-99
DOI: 10.1055/a-0857-3117
SOP / Arbeitsablauf
Georg Thieme Verlag KG Stuttgart · New York

Therapie der Harninkontinenz

Isabella Maria Zraik
,
Joachim Grosse
Further Information

Publication History

Publication Date:
23 July 2019 (online)

Also available at
    Permissions and Reprints All articles of this category

Definition

Harninkontinenz, als Symptom einer Störung der Speicherfunktion der Harnblase, ist definiert als jegliche Form von unwillkürlichem Urinverlust. Vor Einleitung einer medikamentösen Therapie ist die Kenntnis der verschiedenen nicht neurogenen Harninkontinenz-Formen gemäß der aktuellen ICS- und EAU-Guidelines essenziell.

 

  • Literatur

  • 1 Abrams P, Andersson KE, Brubaker L. et al. 3rd International Consultation on Incontinence. Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence 2005. Im Internet: http://www.ics.org/Publications/ICI_3/v2.pdf/summary.pdf
  • 2 Ascherman JA, Knowles SL, Attkiss K. Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 2000; 45: 438-441
    CrossrefPubMedSearch in Google Scholar
  • 3 Berghammer P, Pöhnl R, Baur M, Dittrich C. Docetaxel extravasation. Support Care Cancer 2001; 9: 131-134
    CrossrefPubMedSearch in Google Scholar
  • 4 Bertelli G, Dini D, Forno GB. et al. Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol 1994; 120: 505-506
    CrossrefPubMedSearch in Google Scholar
  • 5 Bertelli G, Gozza A, Forno GB. et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13: 2851-2855
    CrossrefPubMedSearch in Google Scholar
  • 6 Dellas C. Crashkurs Pharmakologie. 3. Aufl.. München: Elsevier; 2011
    Search in Google Scholar
  • 7 Füllhase C, Chapple C, Cornu JN. et al. Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 2013; 64: 228-243
    CrossrefPubMedSearch in Google Scholar
  • 8 Gilbar PJ, Carrington CV. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags. J Oncol Pharm Pract 2006; 12: 113-118
    CrossrefPubMedSearch in Google Scholar
  • 9 Grabe M, Bartoletti R, Bjerklund-Johansen TE. European Association of Urology 2014. Guidelines on Urological Infections. Im Internet: https://uroweb.org/wp-content/uploads/19-Urological-infections_LR.pdf
  • 10 Gravas S, Bachmann A, Descazeaud A. et al. Members of the European Association of Urology (EAU) Guidelines Office. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). In: EAU Guidelines 2014 Im Internet: http://www.uroweb.org/guidelines/online-guidelines
  • 11 Herlemann A, Gratzke C, Andersson KE. et al. Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors. Urologe 2013; 52: 204-211
    CrossrefPubMedSearch in Google Scholar
  • 12 Jordan K, Grothe W, Schmoll HJ. Extravasation zytotoxischer Substanzen: Prävention und Therapie. Dtsch Med Wochenschr 2005; 130: 33-37
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Langer SW. Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther 2007; 7: 1081-1088
    CrossrefPubMedSearch in Google Scholar
  • 14 Leyh H, Necknig U. Benignes Prostatasyndrom. In: Schmelz HU, Sparwasser C, Weidner W. (Hrsg.) Facharztwissen Urologie. 2. Aufl.. Heidelberg: Springer; 2010: 593-602
    CrossrefSearch in Google Scholar
  • 15 Luca MG, Bedretdinova D, Bosch LHR. et al. Members of the European Association of Urology (EAU) Guidelines Office. Guidelines on Urinary Incontinence, In: EAU Guidelines 2014. Im Internet: http://www.uroweb.org/guidelines/online-guidelines
  • 16 Luke E. Mitoxantrone-induced extravasation. Oncol Nurs Forum 2005; 32: 27-29
    CrossrefPubMedSearch in Google Scholar
  • 17 Mouridsen HT, Langer SW, Buter J. et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007; 18: 546-550
    CrossrefPubMedSearch in Google Scholar
  • 18 Nogler-Semenitz E, Mader I, Fürst-Weger P. et al. Extravasation zytotoxischer Substanzen. Wien Klin Wochenschr 2004; 116: 289-295
    CrossrefPubMedSearch in Google Scholar
  • 19 S3-Leitlinie Harnwegsinfektionen. AWMF-Register-Nr. 043/044.
  • 20 Sauerland C, Engelking C, Wickham R, Corbi D. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006; 33: 1134-1141
    CrossrefPubMedSearch in Google Scholar
  • 21 Seitz M, Herlemann A, Magistro G, Stief CG. Diagnostics of benign prostate syndrome. Urologe 2013; 52: 193-196
    CrossrefPubMedSearch in Google Scholar
  • 22 Strittmacher F, Madersbacher S, Stief CG. et al. Importance of adrenoceptor blockers and alpha reductase inhibitors. Monotherapy for treatment of benign prostate syndrome. Urologe 2013; 52: 197-203
    CrossrefPubMedSearch in Google Scholar
  • 23 Wickham R, Engelking C, Sauerland C, Corbi D. Vesicant extravasation part II: Evidence-based management and continuing controversies. Oncol Nurs Forum 2006; 33: 1143-1150
    CrossrefPubMedSearch in Google Scholar
  • 24 Wefer B, Loch A. Harninkontinenz im Erwachsenenalter. In: Schmelz HU, Sparwasser C, Weidner W. Facharztwissen Urologie. 2. Aufl.. Heidelberg: Springer; 2010: 669-696
    CrossrefSearch in Google Scholar